Bernhard Nocht Clinic for Tropical Medicine, I, Department of Tropical Medicine, University Medical Center Hamburg-Eppendorf, Bernhard-Nocht-Strasse 74, 20359 Hamburg, Germany.
Malar J. 2011 Sep 7;10:256. doi: 10.1186/1475-2875-10-256.
Rapid and fast acting anti-malarials are essential to treat severe malaria. Quinine has been the only option for parenteral therapy until recently. While current evidence shows that intravenous artesunate is more effective than quinine in treating severe malaria in endemic countries, some questions remain regarding safety profiles and drug resistance. For imported severe malaria, additional unanswered questions are related to generalizability of the findings from endemic countries and to legal aspects, as there is no Good Manufacturing Practice-conform drug available yet. Here, the implications of existing evidence for the treatment of imported severe malaria are discussed.
快速而强效的抗疟药物对于治疗重症疟疾至关重要。奎宁一直是唯一可供选择的注射用药物，直到最近。虽然目前的证据表明，在疟疾流行地区，静脉内青蒿琥酯治疗重症疟疾比奎宁更有效，但关于安全性和耐药性方面仍存在一些问题。对于输入性重症疟疾，还有一些未解决的问题与流行地区的研究结果的普遍性以及法律方面有关，因为目前还没有符合良好生产规范的药物。在此，讨论了现有证据对输入性重症疟疾治疗的影响。
